ANTX trades 109.3% below Wall Street's consensus target of $9.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes ANTX achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 8 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 8, 2026, AN2 Therapeutics, Inc. (ANTX) has a Wall Street consensus price target of $9.00, based on estimates from 8 covering analysts. With the stock currently trading at $4.30, this represents a potential upside of +109.3%. The company has a market capitalization of $118M.
Analyst price targets range from a low of $9.00 to a high of $9.00, representing a 0% spread in expectations. The median target of $9.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 5 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, ANTX trades at a trailing P/E of -3.7x. Analysts expect EPS to grow +5.4% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
INSMInsmed Incorporated | $24.5B | $112.84 | $204.42 | +81.2% | Buy | — | 35 |
SPROSpero Therapeutics, Inc. | $125M | $2.16 | — | — | Buy | — | 13 |
PRAXPraxis Precision Medicines, Inc. | $9.4B | $323.95 | $589.00 | +81.8% | Buy | — | 16 |
ENTAEnanta Pharmaceuticals, Inc. | $331M | $14.26 | $20.00 | +40.3% | Buy | — | 19 |
IDYAIDEAYA Biosciences, Inc. | $3.6B | $40.51 | $58.67 | +44.8% | Buy | — | 25 |
TARSTarsus Pharmaceuticals, Inc. | $2.6B | $60.89 | $68.00 | +11.7% | Buy | — | 9 |
NKTRNektar Therapeutics | $1.5B | $74.90 | $149.60 | +99.7% | Buy | — | 33 |
CRLCharles River Laboratories International, Inc. | $11.0B | $228.68 | $222.11 | -2.9% | Buy | 20.6x | 37 |
MEDPMedpace Holdings, Inc. | $15.6B | $546.29 | $498.86 | -8.7% | Hold | 32.1x | 19 |
PFEPfizer Inc. | $136.9B | $24.07 | $26.75 | +11.1% | Hold | 8.1x | 39 |
Quick answers to the most common questions about buying ANTX stock.
The consensus Wall Street price target for ANTX is $9, representing 109.3% upside from the current price of $4.3. With 8 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
ANTX has a consensus rating of "Buy" based on 8 Wall Street analysts. The rating breakdown is predominantly bullish, with 5 Buy/Strong Buy ratings. The consensus 12-month price target of $9 implies 109.3% upside from current levels.
ANTX's current price is $4.3 with a consensus target of $9 (109.3% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $9 for ANTX, while the most conservative target is $9. The consensus of $9 represents the median expectation. These targets typically reflect 12-month expectations.
ANTX is moderately covered, with 8 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 3 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month ANTX stock forecast based on 8 Wall Street analysts shows a consensus price target of $9, with estimates ranging from $9 (bear case) to $9 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on ANTX, with a "Buy" consensus rating and $9 price target (109.3% upside). 5 of 8 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
ANTX analyst price targets range from $9 to $9, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $9 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.